• Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board
  • Marc de Garidel will not stand for re-election
  • All other members of the Board of Directors will stand for re-election

VIFOR PHARMA ANNOUNCED TODAY THAT THE BOARD OF DIRECTORS WILL PROPOSE TO ELECT JACQUES THEURILLAT AS A MEMBER OF THE BOARD AT THE NEXT ANNUAL SHAREHOLDER MEETING. 

Marc de Garidel, who has been appointed CEO for US biotechnology company, Corvidia Therapeutics, has decided not to stand for re-election as a member of the Vifor Pharma Group Board of Directors. The Vifor Pharma Group Board of Directors will propose Jacques Theurillat to the Vifor Pharma Annual Shareholder Meeting on 15 May 2018.

"We are very pleased to propose Jacques Theurillat for the Vifor Pharma Group Board of Directors," said Etienne Jornod, Executive Chairman of Vifor Pharma Group. "We believe that his expertise and experience will complement the capabilities of the Board on Vifor Pharma Group's way towards becoming a leading global pharmaceutical company."

Jacques Theurillat, a Swiss citizen, is a financial expert with over three decades of leadership experience in healthcare and life sciences companies. From 2008 to 2015, he served as CEO of Ares Life Sciences AG, a privately-owned investment fund for life-sciences companies. He also served as CEO and Chairman of Swiss life-sciences venture financing company, Albea Pharmaceuticals AG, and in various leadership positions at Serono SA from 1996-2006 and from 1988-1993, including Chief Financial Officer; Senior Executive Vice President, Strategic Corporate Development; and Deputy CEO. He was also Managing Director of the Istituto Farmacologico Serono in Rome, where he started in 1994. Jacques Theurillat is currently a partner at the Sofinnova Crossover Fund in Paris and a member of the board at Purdue Inc./Mundipharma, CNH Industrial NV and ADC Therapeutics SA.

"Marc de Garidel has provided valuable insight and expertise regarding the strategic development of Vifor Pharma Group and in particular its products currently being launched in the USA and in Europe. We are very grateful for his support and guidance in our company, and we wish him well in his new role at Corvidia Therapeutics," said Etienne Jornod .

  
FURTHER INFORMATION
       

Media Relations Investor Relations  
Victoria Maier
Senior External Communications Manager
Julien Vignot
Head of Investor Relations
 
Tel.: +41 58 851 80 16 Tel.: +41 58 851 66 90  
E-mail: media@viforpharma.com E-mail: investors@viforpharma.com  
     

Vifor Pharma Group, formerly Galenica Group, is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com.

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/16a0be86-ffd2-4e07-9941-4556ab7fa435

Ads

You May Also Like

Endocyte Reports First Quarter 2016 Financial Results

- Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented ...

IASLC (国際肺癌学会)、肺癌の専門家に、分子検査についてのグローバル調査の参加を促す

胸部悪性腫瘍のグローバルリーダーが、世界中における分子検査の改善を評価するためのアンケート調査を実施デンバー発, July 13, 2018 (GLOBE NEWSWIRE) -- 国際肺癌学会 (International Association for the Study of ...